CAJ | 학술논문

组蛋白乙酰化和去乙酰化程度的失衡,可影响基因转录的正常进行,引起前列腺癌中抑癌基因的失活与原癌基因的激活,从而促进前列腺癌的发生.针对此现象,研究人员发现许多去乙酰化抑制剂可通过抑制组蛋白去乙酰化酶(HDAC)活性而促进前列腺癌细胞的生长阻滞、分化及凋亡等,达到治疗目的,本文主要总结和回顾组蛋白乙酰化抑制剂在前列腺癌临床治疗方面的应用进展.
조단백을선화화거을선화정도적실형,가영향기인전록적정상진행,인기전렬선암중억암기인적실활여원암기인적격활,종이촉진전렬선암적발생.침대차현상,연구인원발현허다거을선화억제제가통과억제조단백거을선화매(HDAC)활성이촉진전렬선암세포적생장조체、분화급조망등,체도치료목적,본문주요총결화회고조단백을선화억제제재전렬선암림상치료방면적응용진전.
The imbalance between histone acetylation and histone deacetylation can lead to the inactivation of suppressor genes and the activation of oncogenes by influencing transcription. Based on this, researchers found that HDAC inhibitors can induce prostate cancer cells growth arrest, differentiation and apoptosis. This review summarizes the advance research of histone deacetylase inhibitors in treatment of prostate cancer.